111 related articles for article (PubMed ID: 33562978)
1. What next in cervical cancer screening?
Sehnal B; Sláma J
Ceska Gynekol; 2020; 85(4):236-243. PubMed ID: 33562978
[TBL] [Abstract][Full Text] [Related]
2. Importance of addition of HPV DNA testing to the cytology based cervical cancer screening and triage of findings with p16/Ki67 immunocytochemistry staining in 35 and 45 years old women LIBUSE trial data analysis.
Sláma J; Dvořák V; Trnková M; Skřivánek A; Hurdálková K; Ovesná P; Nováčková M
Ceska Gynekol; 2020; 85(6):368-374. PubMed ID: 33711896
[TBL] [Abstract][Full Text] [Related]
3. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries.
Cuzick J; Arbyn M; Sankaranarayanan R; Tsu V; Ronco G; Mayrand MH; Dillner J; Meijer CJ
Vaccine; 2008 Aug; 26 Suppl 10():K29-41. PubMed ID: 18847555
[TBL] [Abstract][Full Text] [Related]
4. [Cervical cancer--possibilities of detection of human papillomavirus].
Ondryášová H; Koudeláková V; Hajdúch M
Ceska Gynekol; 2013 Jun; 78(3):289-94. PubMed ID: 23869837
[TBL] [Abstract][Full Text] [Related]
5. [Current limits of cervical cancer prevention in the Czech republic].
Sláma J
Ceska Gynekol; 2017; 82(6):482-486. PubMed ID: 29302983
[TBL] [Abstract][Full Text] [Related]
6. Performance of p16/Ki67 immunostaining, HPV E6/E7 mRNA testing, and HPV DNA assay to detect high-grade cervical dysplasia in women with ASCUS.
Zhu Y; Ren C; Yang L; Zhang X; Liu L; Wang Z
BMC Cancer; 2019 Mar; 19(1):271. PubMed ID: 30917784
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic performance of the E6/E7 mRNA-based Optimygene HR-HPV RT-qDx assay for cervical cancer screening.
Wang HY; Kim H; Park KH
Int J Infect Dis; 2019 Jan; 78():22-30. PubMed ID: 30248464
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic validity of human papillomavirus E6/E7 mRNA test in cervical cytological samples.
Liu TY; Xie R; Luo L; Reilly KH; He C; Lin YZ; Chen G; Zheng XW; Zhang LL; Wang HB
J Virol Methods; 2014 Feb; 196():120-5. PubMed ID: 24216236
[TBL] [Abstract][Full Text] [Related]
9. Correlation between integration of high-risk HPV genome into human DNA detected by molecular combing and the severity of cervical lesions: first results of the EXPL-HPV-002 study.
Bouchilloux S; Fer F; Lemée F; Barradeau S; Dvorak V; Kubickova S; Ventruba P; Tachezy R; Trnková M; Janda P; Abscheidt J; Annibal E; El Mhali D; Garcia F; Kech M; Pilger G; Bensimon A; Mahé F
Ceska Gynekol; 2019; 84(2):84-92. PubMed ID: 31238677
[TBL] [Abstract][Full Text] [Related]
10. [Importance of the Pap smear in the age of HPV testing].
Ghisu GP
Ther Umsch; 2021; 78(2):93-98. PubMed ID: 33615865
[TBL] [Abstract][Full Text] [Related]
11. Carcinoma of the uterine cervix in Czech Republic and possibilities of its prevence.
Luňáčková IK; Májek O
Cesk Patol; 2018; 63(4):164-168. PubMed ID: 30497267
[TBL] [Abstract][Full Text] [Related]
12. Human papillomavirus testing for primary cervical cancer screening.
Grce M; Davies P
Expert Rev Mol Diagn; 2008 Sep; 8(5):599-605. PubMed ID: 18785808
[TBL] [Abstract][Full Text] [Related]
13. Implementing specificity of HPV-DNA primary screening in a successful organised cervical cancer prevention programme.
Zappacosta R; Caraceni D; Ciccocioppo L; Rotondo T; Capanna S; Gatta DM; D'Angelo C; Rosini S
Gynecol Oncol; 2013 Mar; 128(3):427-32. PubMed ID: 23200910
[TBL] [Abstract][Full Text] [Related]
14. [Prevalence of anal human papillomavirus infection among women and its relation to cervical HPV infection].
Sehnal B; Driák D; Neumannová H; Kolařík D; Menzlová E; Sláma J
Ceska Gynekol; 2012 Jun; 77(3):210-4. PubMed ID: 22779720
[TBL] [Abstract][Full Text] [Related]
15. Cervical cancer screening program based on primary DNA-HPV testing in a Brazilian city: a cost-effectiveness study protocol.
Teixeira JC; Vale DB; Bragança JF; Campos CS; Discacciati MG; Zeferino LC
BMC Public Health; 2020 Apr; 20(1):576. PubMed ID: 32345284
[TBL] [Abstract][Full Text] [Related]
16. The changes in FIGO staging for carcinoma of the cervix uteri.
Sehnal B; Sláma J; Kmoníčková E; Dubová O; Zikán M
Ceska Gynekol; 2019; 84(3):216-221. PubMed ID: 31324113
[TBL] [Abstract][Full Text] [Related]
17. Human papillomavirus E6/E7 mRNA testing as a predictive marker for cervical carcinoma.
Lie AK; Kristensen G
Expert Rev Mol Diagn; 2008 Jul; 8(4):405-15. PubMed ID: 18598223
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the detection of HPV-16, 18, 31, 33, and 45 by type-specific DNA- and E6/E7 mRNA-based assays of HPV DNA positive women with abnormal Pap smears.
Salimović-Bešić I; Tomić-Čiča A; Smailji A; Hukić M
J Virol Methods; 2013 Dec; 194(1-2):222-8. PubMed ID: 24036071
[TBL] [Abstract][Full Text] [Related]
19. Determinants of Viral Oncogene E6-E7 mRNA Overexpression in a Population-Based Large Sample of Women Infected by High-Risk Human Papillomavirus Types.
Giorgi Rossi P; Bisanzi S; Allia E; Mongia A; Carozzi F; Gillio-Tos A; De Marco L; Ronco G; Gustinucci D; Del Mistro A; Frayle H; Iossa A; Fantacci G; Pompeo G; Cesarini E; Bulletti S; Passamonti B; Rizzi M; Penon MG; Barca A; Benevolo M
J Clin Microbiol; 2017 Apr; 55(4):1056-1065. PubMed ID: 28100595
[TBL] [Abstract][Full Text] [Related]
20. Use of Cytology, E6/E7 mRNA, and p16INK4a-Ki-67 to Define the Management of Human Papillomavirus (HPV)-Positive Women in Cervical Cancer Screening.
Gustinucci D; Giorgi Rossi P; Cesarini E; Broccolini M; Bulletti S; Carlani A; D'angelo V; D'amico MR; Di Dato E; Galeazzi P; Malaspina M; Martinelli N; Spita N; Tintori B; Giaimo MD; Passamonti B
Am J Clin Pathol; 2016 Jan; 145(1):35-45. PubMed ID: 26712869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
